<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00079248</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000355122</org_study_id>
    <secondary_id>CRUK-HRT</secondary_id>
    <secondary_id>EU-20112</secondary_id>
    <secondary_id>ISRCTN29941643</secondary_id>
    <nct_id>NCT00079248</nct_id>
  </id_info>
  <brief_title>Hormone Replacement Therapy in Relieving Menopausal Symptoms in Postmenopausal Women With Previous Stage I or Stage II Breast Cancer</brief_title>
  <official_title>UK Trial Of Hormone Replacement Therapy (HRT) In Women With A History Of Early Stage Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute of Cancer Research, United Kingdom</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Hormone replacement therapy may be effective in relieving symptoms of menopause,&#xD;
      such as hot flashes, night sweats, and vaginal dryness, without causing a recurrence of&#xD;
      breast cancer.&#xD;
&#xD;
      PURPOSE: This randomized clinical trial is studying hormone replacement therapy to see how&#xD;
      well it works in relieving symptoms of menopause in postmenopausal women with previous stage&#xD;
      I or stage II breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Compare disease-free survival and overall survival of postmenopausal women with prior&#xD;
           stage I or II breast cancer treated with hormone replacement therapy (HRT) vs&#xD;
           nonhormonal alternatives to HRT.&#xD;
&#xD;
        -  Compare relief of menopausal symptoms and quality of life of patients treated with these&#xD;
           regimens.&#xD;
&#xD;
        -  Compare cardiovascular and osteoporotic events in patients treated with these regimens.&#xD;
&#xD;
      OUTLINE: This is a randomized, multicenter study. Patients are stratified according to&#xD;
      participating center, age (&lt; 40 years vs ≥ 40 years), and years from diagnosis (≤ 2 vs &gt; 2 to&#xD;
      &lt; 5 vs ≥ 5). Patients are randomized to 1 of 2 treatment arms.&#xD;
&#xD;
        -  Arm I: Patients receive oral or transdermal HRT comprising estrogen with or without&#xD;
           progesterone for at least 2 years.&#xD;
&#xD;
        -  Arm II: Patients are offered advice on nonhormonal HRT alternatives. Menopausal symptoms&#xD;
           are assessed at baseline, at 3, 6, and 12 months, every 6 months for 4 years, and then&#xD;
           annually thereafter. Quality of life is assessed at baseline, at 3, 6, and 12 months,&#xD;
           every 6 months for 1 year, and then annually thereafter.&#xD;
&#xD;
      Patients are followed every 6 months for 3 years and then annually thereafter.&#xD;
&#xD;
      Peer Reviewed and Funded or Endorsed by Cancer Research UK&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 2,800-3,000 patients (1,400-1,500 per treatment arm) will be&#xD;
      accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>March 2002</start_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Supportive Care</primary_purpose>
  </study_design_info>
  <condition>Breast Cancer</condition>
  <condition>Hot Flashes</condition>
  <condition>Menopausal Symptoms</condition>
  <condition>Osteoporosis</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>therapeutic progesterone</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>conjugated estrogens</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Prior diagnosis of stage I or II breast cancer&#xD;
&#xD;
               -  No clinical evidence of recurrence&#xD;
&#xD;
          -  Meets criteria for 1 of the following:&#xD;
&#xD;
               -  Amenorrheic for at least the past 6 months&#xD;
&#xD;
                    -  Radiotherapy- or chemically-induced ovarian suppression allowed&#xD;
&#xD;
               -  Prior surgical bilateral oophorectomy&#xD;
&#xD;
          -  Experiencing vasomotor symptoms (i.e., hot flashes or night sweats) with or without&#xD;
             vaginal dryness&#xD;
&#xD;
          -  No undiagnosed postmenopausal bleeding&#xD;
&#xD;
          -  No ductal carcinoma in situ or lobular carcinoma in situ alone&#xD;
&#xD;
          -  Hormone receptor status:&#xD;
&#xD;
               -  Not specified&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  Postmenopausal&#xD;
&#xD;
        Sex&#xD;
&#xD;
          -  Female&#xD;
&#xD;
        Menopausal status&#xD;
&#xD;
          -  Postmenopausal&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  No severe, active liver disease with abnormal liver function tests&#xD;
&#xD;
          -  No acute, intermittent porphyria&#xD;
&#xD;
          -  Fibrinolysis and coagulation normal&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No prior deep vein thrombosis&#xD;
&#xD;
               -  Thrombophlebitis or superficial phlebitis alone allowed&#xD;
&#xD;
          -  No prior retinal vein thrombosis&#xD;
&#xD;
        Pulmonary&#xD;
&#xD;
          -  No prior pulmonary embolism&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant&#xD;
&#xD;
          -  No prior alcohol, drug, or chemical abuse&#xD;
&#xD;
          -  No other prior or concurrent malignancy except nonmelanoma skin cancer or carcinoma in&#xD;
             situ of the cervix&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  No concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  More than 3 months since prior oral or transdermal hormone replacement therapy (HRT)&#xD;
&#xD;
          -  More than 5 years since prior HRT implant&#xD;
&#xD;
          -  No other concurrent HRT&#xD;
&#xD;
          -  No concurrent gonadotropin-releasing hormone agonists (e.g., goserelin) if less than 2&#xD;
             years of planned treatment remains&#xD;
&#xD;
          -  No other concurrent low-dose progestins&#xD;
&#xD;
          -  No concurrent tibolone&#xD;
&#xD;
          -  No concurrent phytoestrogens (e.g., black cohosh, red clover, or soy)&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No concurrent Hypericum perforatum (St. John's wort)&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jenni Parmar, RN</last_name>
    <affiliation>Institute of Cancer Research, United Kingdom</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institute of Cancer Research - UK</name>
      <address>
        <city>Sutton</city>
        <state>England</state>
        <zip>SM2 5NG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>June 2005</verification_date>
  <study_first_submitted>March 8, 2004</study_first_submitted>
  <study_first_submitted_qc>March 9, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 10, 2004</study_first_posted>
  <last_update_submitted>May 9, 2009</last_update_submitted>
  <last_update_submitted_qc>May 9, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 12, 2009</last_update_posted>
  <keyword>osteoporosis</keyword>
  <keyword>stage I breast cancer</keyword>
  <keyword>stage II breast cancer</keyword>
  <keyword>menopausal symptoms</keyword>
  <keyword>hot flashes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Hot Flashes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Progesterone</mesh_term>
    <mesh_term>Estrogens, Conjugated (USP)</mesh_term>
    <mesh_term>Estrogens</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

